Cargando…
Preclinical therapeutic efficacy of a novel blood-brain barrier-penetrant dual PI3K/mTOR inhibitor with preferential response in PI3K/PTEN mutant glioma
Glioblastoma (GBM) is an ideal candidate disease for signal transduction targeted therapy because the majority of these tumors harbor genetic alterations that result in aberrant activation of growth factor signaling pathways. Loss of heterozygosity of chromosome 10, mutations in the tumor suppressor...
Autores principales: | Koul, Dimpy, Wang, Shuzhen, Wu, Shaofang, Saito, Norihiko, Zheng, Siyuan, Gao, Feng, Kaul, Isha, Setoguchi, Masaki, Nakayama, Kiyoshi, Koyama, Kumiko, Shiose, Yoshinobu, Sulman, Erik P., Hirota, Yasuhide, Yung, W.K. Alfred |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5400620/ https://www.ncbi.nlm.nih.gov/pubmed/28423515 http://dx.doi.org/10.18632/oncotarget.15566 |
Ejemplares similares
-
The PTEN–PI3K Axis in Cancer
por: Papa, Antonella, et al.
Publicado: (2019) -
APOBEC3G acts as a therapeutic target in mesenchymal gliomas by sensitizing cells to radiation-induced cell death
por: Wang, Yu, et al.
Publicado: (2017) -
Biological characterization of SN32976, a selective inhibitor of PI3K and mTOR with preferential activity to PI3Kα, in comparison to established pan PI3K inhibitors
por: Rewcastle, Gordon W, et al.
Publicado: (2017) -
Divergent Roles of PI3K Isoforms in PTEN-Deficient Glioblastomas
por: Xie, Shaozhen, et al.
Publicado: (2020) -
The orchestrated signaling by PI3Kα and PTEN at the membrane interface
por: Kotzampasi, Danai Maria, et al.
Publicado: (2022)